| WARF: P01315US |  |
| Preparations and Uses of an Endogenous Aryl Hydrocarbon Receptor |
| INVENTORS | • | Jiasheng Song, Hector DeLuca, Richard Peterson, Margaret Clagett-Dame, Rafal Sicinski, William Westler |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a novel endogenous AhR ligand.
OVERVIEW
The aryl hydrocarbon receptor (AhR) is a ligand-inducible transcription factor that mediates a broad spectrum of biological processes. It is a member of the emerging bHLH/PAS (basic Helix-Loop-Helix/Pas-Arnt-Sim) super family of transcription factors. Many synthetic chemical agents are recognized ligands for AhR, but endogenous AhR ligands have not yet been identified.
THE INVENTION
UW-Madison researchers have identified a novel endogenous AhR ligand, 2-(1`H-indole-3`-carbonyl)-thiazole-4-carboxylic acid methyl ester. This AhR ligand likely regulates cell growth and differentiation in a highly tissue-specific manner, and may also exhibit responses similar to those caused by some of the known AhR ligands. Determining the normal physiological function(s) of this ligand should provide important new information on the mechanism of AhR-mediated biological responses. In addition, this endogenous AhR ligand and its various analogs should be useful for a wide variety of therapeutic applications.
APPLICATIONS
Potential applications include:- Reducing body weight of humans or animals
- Treating transplant rejection, autoimmune diseases, immunodeficiency disorders or chronic infectious diseases
- Treating breast cancer or osteoporosis
- Treating prostate cancer, male pattern baldness, virilizing syndromes in women or precocious puberty in boys
- Inhibiting sex drive in men who are sex offenders
- Treating pulmonary disorders such as chronic obstructive pulmonary disease, asthma, emphysema, bronchitis, RQ mismatch or acute pulmonary dysfunction
- Controlling angiogenesis in invasive cancer
KEY BENEFITS
- May increase understanding of the physiological functions of the AhR system and the potential therapeutic benefits this system may offer
- Ligand and its analogs may be administered orally or parenterally.
ADDITIONAL INFORMATION
Related Technologies
WARF reference number P02237US describes the synthesis of indole thiazole compounds as ligands for the AH receptor.
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Oncology & hematology
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
